FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to compounds of formulawherein m is equal to 0, 1, 2； n is equal to 0, 1, 2, 3； each p, s, t is equal to 0 or 1； X represents CHR8 wherein R8 represents hydrogen； represents -CR9=C<；, and then a dash line represents a bond, R9 independently represents hydrogen or C1-6-alkyl, or wherein R9 together with one of R2 or R20 forms a direct bond； R1 represents hydrogen； R2 and R20 are specified in: halogen, cyano, polyhalogen-C1-6-alkyl, C1-6-alkyl, morpholinyl, C1-6-alkyloxy with any of said groups is optionally and independently substituted by hydroxy, NR21R22 wherein R21 and R22 are independently specified in hydrogen, C1-6-alkylcarbonyl； or R2 and R20 together with a phenyl cycle whereto attached form a naphthaline group； or one of R2 or R20 have the values specified above, and the other of R2 or R20 together with R9 form a direct bond； R3 represents hydrogen； R4 and R5 independently represent hydrogen, C1-6-alkyl, hydroxy-C1-6-alkyl, C2-6-alkenyl or C1-6-alkyloxy； or R6 represents hydrogen； when p is equal to 1, then R7 represents hydrogen； Z represents one of the radicals presented in the patent claim. Also, the invention refers to a based pharmaceutical composition, using the compounds of formula (I) for producing the drug preparation for treating the disorders medicated by p53-MDM2 interaction for treating cancer, and to methods for producing the compounds of formula (I).EFFECT: preparing the compounds of formula (I) as p53-MDM2 interaction inhibitors.13 cl, 5 tbl, 31 exИзобретение относится к соединениям формулы (I), где m равен 0, 1, 2； n равен 0, 1, 2, 3； каждый p, s, t равен 0 или 1； X представляет собой CHR8, где R8 представляет собой водород； представляет собой -CR9=C<；, и тогда пунктирная линия представляет собой связь, R9 представляет собой независимо водород или C1-6-алкил, или где R9 вместе с одним из R2 или R20 образует прямую связь； R1 представляет собой водород； R2 и R20 выбирают из: га
